Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to